World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 20 July 2020
Main ID:  EUCTR2004-002641-12-GB
Date of registration: 30/06/2005
Prospective Registration: No
Primary sponsor: Schwarz Biosciences GmbH
Public title: A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease
Scientific title: A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease
Date of first enrolment: 16/05/2005
Target sample size: 220
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002641-12
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no
Randomised: no
Open:
Single blind:
Double blind:
Parallel group:
Cross over:
Other:
If controlled, specify comparator, Other Medicinial Product:
Placebo:
Other:
 
Phase:  Human pharmacology (Phase I): Therapeutic exploratory (Phase II): Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV):
Countries of recruitment
Austria Italy Spain United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Subject is informed and given ample time and opportunity to think about her/his
participation and has given her/his written informed consent.
2. Subject is willing and able to comply with all trial requirements.
3. Subject has completed Study SP824, SP825, or SP826.
4. Subject, in the opinion of the investigator, would benefit from long-term treatment
of rotigotine.

Are the trial subjects under 18?
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Subject has an ongoing serious adverse event that is assessed as related to
study medication


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Parkinson's disease
Intervention(s)

Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 4.5-

Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 9.0-

Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 13.5-

Product Name: Rotigotine
Product Code: SPM 962
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: Rotigotine
CAS Number: [99755-59-6]
Current Sponsor code: SPM 962
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 18.0-

Primary Outcome(s)
Secondary Objective:
Main Objective: to assess the safety and tolerability of long-term treatment of rotigotine, administered up to 2 years, until rotigotine is commercially available or until the sponsor closes the study, whichever comes first, in subjects with idiopathic Parkinson's disease
Primary end point(s): • Frequency and severity of adverse events (AEs), as reported spontaneously by the
subject or observed by the investigator, recorded over the course of the trial
• Changes in vital signs, body weight, electrocardiograms (ECGs), and clinical
laboratory values over the course of the trial
• Changes in physical and neurological examination data over the course of the trial
• Changes in Epworth Sleepiness Scale (ESS) scores over the course of the trial
• Adhesiveness of the patch
• Clinical Global Impression (CGI) over the course of the trial
• Patient Global Impression (PGI) over the course of the trial
• Change from baseline in UPDRS Part I scores over the course of the trial
• Change from baseline in UPDRS Part II scores over the course of the trial
• Change from baseline in UPDRS Part III scores over the course of the trial
• Change from baseline in UPDRS Part IV scores over the course of the trial
• Change from pretreatment in Hoehn and Yahr stage over the course of the trial
• Change in quality of life, from baseline to end of the trial, as assessed using the
short-form Parkinson's Disease Questionnaire (PDQ-8)
• Change in quality of sleep, from baseline to end of the trial, as assessed using the
Parkinson's Disease Sleep Scale (PDSS)
• Rating of patch application site preference and satisfaction with trial treatment as
assessed by a patient preference questionnaire
Baseline for this open-label extension trial is defined as the subject’s baseline in SP824, SP825, or SP826.
Secondary Outcome(s)
Secondary ID(s)
SP833
2004-002641-12-AT
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 30/10/2006
Contact:
Results
Results available: Yes
Date Posted: 23/12/2016
Date Completed: 11/12/2008
URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002641-12/results
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey